Jaguar Animal Health, which is developing an animal formulation of its parent's approved diarrhea treatment, postponed its IPO on Wednesday. The company planned to raise $40 million by offering 5.0 million shares at a price range of $7 to $9. At the...read more
Jaguar Animal Health, a biotech developing gastrointestinal treatments for companion and production animals, announced terms for its IPO on Tuesday. The San Francisco, CA-based company plans to raise $40 million by offering 5.0 million shares at a price range of...read more
Parnell Pharmaceuticals, an Australian maker of osteoarthritis and reproductive drugs for dogs, horses and cows, raised $50 million by offering 5.0 million shares at the revised $10 IPO price. The company had originally filed to offer 3.6 million shares at $17...read more
Parnell Pharmaceuticals, an Australian maker of osteoarthritis and reproductive drugs for dogs, horses and cows, lowered the proposed deal size for its upcoming IPO on Wednesday. The company now plans to raise $50 million by offering 5.0 million shares at $10...read more
Dog diarrhea deal drops out: Jaguar Animal Health postpones IPO
Jaguar Animal Health, which is developing an animal formulation of its parent's approved diarrhea treatment, postponed its IPO on Wednesday. The company planned to raise $40 million by offering 5.0 million shares at a price range of $7 to $9. At the...read more
Year's number 2 IPO: Dog diarrhea biotech Jaguar Animal Health sets terms for $40 million IPO
Jaguar Animal Health, a biotech developing gastrointestinal treatments for companion and production animals, announced terms for its IPO on Tuesday. The San Francisco, CA-based company plans to raise $40 million by offering 5.0 million shares at a price range of...read more
Parnell Pharmaceuticals prices IPO at $10, well below the original range
Parnell Pharmaceuticals, an Australian maker of osteoarthritis and reproductive drugs for dogs, horses and cows, raised $50 million by offering 5.0 million shares at the revised $10 IPO price. The company had originally filed to offer 3.6 million shares at $17...read more
Parnell Pharmaceuticals drops proposed IPO price to $10 and increases shares offered
Parnell Pharmaceuticals, an Australian maker of osteoarthritis and reproductive drugs for dogs, horses and cows, lowered the proposed deal size for its upcoming IPO on Wednesday. The company now plans to raise $50 million by offering 5.0 million shares at $10...read more